EVOTF Stock - Evotec SE
Unlock GoAI Insights for EVOTF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $796.97M | $781.43M | $751.45M | $618.03M | $500.92M |
| Gross Profit | $114.88M | $175.05M | $174.06M | $151.54M | $125.74M |
| Gross Margin | 14.4% | 22.4% | 23.2% | 24.5% | 25.1% |
| Operating Income | $-142,522,000 | $-47,507,000 | $20.85M | $41.00M | $48.52M |
| Net Income | $-196,078,000 | $-83,913,000 | $-175,655,000 | $215.51M | $6.28M |
| Net Margin | -24.6% | -10.7% | -23.4% | 34.9% | 1.3% |
| EPS | $-1.11 | $-0.47 | $-0.99 | $1.30 | $0.04 |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Visit WebsiteEarnings History & Surprises
EVOTFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 5, 2025 | $-0.16 | $-0.28 | -82.7% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.15 | $-0.29 | -93.2% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.09 | $-0.18 | -105.5% | ✗ MISS |
Q2 2025 | Apr 17, 2025 | $0.03 | $-0.24 | -867.9% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.12 | $-0.25 | -100.1% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.07 | $-0.58 | -667.8% | ✗ MISS |
Q2 2024 | May 22, 2024 | $0.01 | $-0.13 | -1612.8% | ✗ MISS |
Q1 2024 | Feb 26, 2024 | — | $-0.10 | — | — |
Q3 2023 | Sep 30, 2023 | $-0.06 | $-0.23 | -311.9% | ✗ MISS |
Q3 2023 | Aug 29, 2023 | — | $-0.09 | — | — |
Q1 2023 | Mar 31, 2023 | $-0.12 | $-0.09 | +28.8% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | $0.18 | $-0.17 | -192.2% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.01 | $-0.27 | -1736.7% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.17 | $-0.16 | +4.6% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.02 | $-0.41 | -2150.3% | ✗ MISS |
Q2 2022 | Apr 12, 2022 | $0.14 | $-0.21 | -247.6% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $0.06 | $0.82 | +1266.7% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.01 | $-0.03 | -250.1% | ✗ MISS |
Q2 2021 | May 11, 2021 | $0.02 | $0.32 | +1500.0% | ✓ BEAT |
Q1 2021 | Mar 25, 2021 | — | $0.00 | — | — |
Latest News
Frequently Asked Questions about EVOTF
What is EVOTF's current stock price?
What is the analyst price target for EVOTF?
What sector is Evotec SE in?
What is EVOTF's market cap?
Does EVOTF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to EVOTF for comparison